Flow Chemistry Improves Control of Nanoprecipitation
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Syrris, a world leader in chemistry product innovation, continues to support pioneering research into nanoparticle drug encapsulation, thanks to its award-winning Asia range of advanced flow chemistry modules. Professor Nicola Tirelli, a senior researcher at the Laboratory of Polymers and Biomaterials at the Italian Institute of Technology, explained: “Controlling the average size of nanoparticles, and the size distribution, is paramount for regulating both cellular uptake and drug release profiles – factors that strongly influence therapeutic efficacy.”
“Traditionally, particle production via nanoprecipitation has been achieved with batch processes, which have struggled to reproducibly control particle size and distribution. The Asia microfluidics platform offers much higher levels of control, as mixing takes place in channels of controlled size and geometry, and almost invariably under laminar flow. This results in the reproducible production of homogeneous particles, with a considerably narrower size distribution than most equivalent batch processes – with clear benefits for drug delivery – and offers significant advantages during research and development, as it is more straightforward to rationalize biological results when particle size is consistent. It is also easier to transfer the process to a good laboratory practice or good manufacturing practice environment, which is a necessary step for clinical translation of encapsulated drug products.”
“Traditionally, particle production via nanoprecipitation has been achieved with batch processes, which have struggled to reproducibly control particle size and distribution. The Asia microfluidics platform offers much higher levels of control, as mixing takes place in channels of controlled size and geometry, and almost invariably under laminar flow. This results in the reproducible production of homogeneous particles, with a considerably narrower size distribution than most equivalent batch processes – with clear benefits for drug delivery – and offers significant advantages during research and development, as it is more straightforward to rationalize biological results when particle size is consistent. It is also easier to transfer the process to a good laboratory practice or good manufacturing practice environment, which is a necessary step for clinical translation of encapsulated drug products.”
